Abstract
The behavior of inhibitors of monoamine oxidase-A (MAO-A) is considered in terms of the possibility of having an effective antidepressant that does not give rise to hypertensive interactions with dietary tyramine. Studies with punch-biopsy samples of human intestine and rat intestinal samples show MAO-A to be the predominant form of the enzyme in both species. Transport studies with everted rat intestinal preparations indicate that tyramine is extensively metabolized during transport through the intestine. Selective inhibition of MAO-A by clorgyline results in a large increase in the amount of unchanged tyramine transported, whereas selective inhibition of MAO-B with L-deprenyl (selegiline) has no significant effect. The behavior of reversible MAO-A inhibitors can significantly reduce, but not entirely eliminate, these effects on the intestinal metabolism of tyramine, but only if the inhibition is competitive in nature.
Similar content being viewed by others
References
Tipton, K. F. 1989. Monoamine oxidase inhibitors as antidepressants. Pages 1–24,in Tipton, K. F. and Youdim, M. B. H. (eds.) Biochemical and Pharmacological Aspects of Depression. Taylor & Francis, London.
Blackwell, B. 1963. Hypertensive crisis due to monoamine oxidase inhibitors. Lancet (ii): 849–951.
Davis, D. S., Tasuhara, H., Boobis, A. R., and George, C. F. 1984. The effects of reversible and irreversible inhibitors of monoamine oxidase on tyramine deamination in dog intestine. Pages 443–448in Tipton, K. F., Dostert, P. and Strolin Benedetti, A. (eds.) Monoamine Oxidase and Disease. Academic Press, London.
Dostert, P. 1984. Myth and reality of the classical MAO inhibitors, reasons for seeking a new generation. Pages 487–497in Tipton, K. F., Dostert, P. and Strolin Benedetti, A. (eds.) Monoamine Oxidase and Disease. Academic Press, London.
Da Prada, M., Zürcher, G., Würthrich, I., and Haefely, W. E. 1988. Ontyramine, food beverages and the reversible MAO inhibitor moclobemide. J. Neural. Transmiss. 26 (Suppl.): 33–56.
Wheatley, A. M., and Tipton, K. 1987. Determination of tyramine in alcoholic and non-alcoholic beers by high performance liquid chromatography with electrochemical detection. J. Food. Biochem. 11:133–142.
Sen, N. P. 1969. Analysis and significance of tyramine in foods. J. Food. Sci. 34:22–26.
Dollery, C. T., Brown, M. J., Davies, D. S., and Strolin Benedetti, M. 1984. Pressor amines and monoamine oxidase inhibitors. Pages 429–441in Tipton, K. F., Dostert, P., and Strolin Benedetti, A. (eds.) Monoamine Oxidase and Disease. Academic Press, London.
Youdim, M. B. H., Finberg, J. P. M., and Tipton, K. F. 1988. Monoamine oxidase. Pages 119–192in Trendelenburg, U. and Weiner, N. (eds.) Handbook of Experimental Pharmacology, vol. 90. Springer Verlag, Berlin.
Tipton, K. F. 1985. Determination of monoamine oxidase. Meth. Find. Exp. Clin. Pharmacol. 7:361–367.
Hasan, F., McCrodden, J. M., Kennedy, N. P., and Tipton, K. F. 1988. The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J. Neural. Transmiss. 26, (Suppl.): 1–9.
Strolin Benedetti, M., Boucher, T., Carlsson, A., and Fowler, C. J. 1983. Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Biochem. Pharmacol. 32:47–52.
Valoti, M., Tipton, K. F., and Sgaragli, G. P. 1992. Oxidative ring-coupling of tyrosine and its derivatives by purified rat intestinal peroxidase. Biochem. Pharmacol. 43:945–951.
Rein, G., Glover, V., and Sandler, M. 1982. Multiple forms of phenolsulphotransferases in human tissues. Biochem. Pharmacol. 31:1893–1897.
Biek, P. R., Kemmler, H., Henriot, S., and Tipton, K. F. 1988. Evidence for “local” gastroinestinal effects of MAO inhibition on metabolism and transport of tyramine in human subjects. Pharmacol. Res. Commun. 20:129–130.
Mendis, N., Pare, C. M. B., Sandler, M., Glover, V., and Stern, G. M. 1981. Is the failure of (−)-deprenyl, a selective monoamine oxidase-B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacol. 73:87–90.
Pare, C. M. B. 1984. Clinical studies with monoamine oxidase inhibitors and tricyclic antidepressants. Pages 469–478in Tipton, K. F., Dostert, P. and Strolin Benedetti, A. (eds.) Monoamine Oxidase and Disease. Academic Press, London.
Erwin, V. G., and Deitrich, R. A. 1971. The labellingin vivo of monoamine oxidase by [14C]-pargyline: a tool for studying the synthesis of the enzyme. Mol. Pharmacol. 7:219–228.
Della Corte, L., and Tipton, K. F. 1980. The turnover of the A- and B-forms of monoamine oxidase in rat liver. Biochem. Pharmacol. 29:811–815.
Neff, N. H., and Goridis, C. 1972. Neuronal monoamine oxidase: specific enzyme types and their rates of formation. Adv. Biochem. Psychopharmacol. 5:307–323.
Callingham, B. A., Mazel, P. and Porter, J. C. 1985. Some properties of amine oxidase activities in the rat intestine. Br. J. Pharmacol. 86:553 P.
Arnett, C. D., Fowler, J. S., MarGregor, R. R., Schyler, D. J., Wolf, A. P., Langrström, B., and Haldin, C. J. 1987. Turnover of brain monoamine oxidase measureed in vivo by positron emission tomography using L-[14C] deprenyl. J. Neurochem. 49:522–527.
Felner, A. E., and Waldmeier, P. C. 1979. Cumulative effects of irreversible MAO inhibitors in vivo. Biochem. Pharmacol. 28:995–1002.
Waldmeier, P. C., Felner, A. E., and Tipton, K. F. 1983. The monoamine oxidase inhibiting properties of CGP 11305A. Eur. J. Pharmacol. 94:73–83.
Tipton, K. F. and Fowler, C. J. 1984. The kinetics of monoamine oxidase inhibitors in relation to their clinical behaviour. Pages 27–40 in Tipton, K. F., Dostert, P. and Strolin Benedetti, A. (eds.) Monoamine Oxidase and Disease. Academic Press, London.
Da Prada, M., Kettler, R. M., Cesura, A. M., and Richards 1988. Reversible enzyme-activated monoamine oxidase inhibitors: new advances. Pharmacol. Res. Commun. 20, Suppl. 4:21–23.
Anderson, M. C., Waldmeier, P. C., and Tipton, K. F. 1991. The inhibition of monoamine oxidase by brofaromine. Biochem. Pharmacol. 41:1871–1877.
Da Prada, M., Kettler, R., Keller, H. H., Cesura, A. M., Richards, J. G., Saura Marti, J., Mugli-Maniglio, D., Wyss, P-C., Kyburz, E., and Imhof, R. 1990. From moclobemide to Ro 196327: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors J. Neural Transmiss. 29 (Suppl.): 279–292.
Callingham, B. A. 1989. Biochemical aspects of the pharmacology of moclobemide- The implications of animal studies. Br. J. Psychiat. 115 (Suppl. 6):53–60.
Knoll, J. 1989. The pharmacology of selegiline/(−) deprenyl. New aspects. Acta Neurol. Scand. 126:83–91.
Knoll, J. 1993. The pharmacological basis of the beneficial effects of (−) deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. J. Neural Transmiss. (in press).
Parkinson Study Group. 1989. Effect of deprenyl on the progression of disability in early Parkinson's disease. New. Engl. J. Med. 321:1364–1371.
Tetrud, J. W. and Langston, J. W. 1989. The effect of deprenyl on the natural history of Parkinson's disease. Science 245:519–522.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Anderson, M.C., Hasan, F., McCrodden, J.M. et al. Monoamine oxidase inhibitors and the cheese effect. Neurochem Res 18, 1145–1149 (1993). https://doi.org/10.1007/BF00978365
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00978365